Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Tumors Harboring NTRK Fusion × larotrectinib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Solid Tumors Harboring NTRK Fusion 2 Neoplasms 2 Tumors Harboring NTRK Fusion 1 Thyroid Neoplasms 1 Sarcoma 1 Salivary Gland Neoplasms 1 Melanoma 1 Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion 1 Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

larotrectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03025360 2019-12-19

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

Approved for marketing

Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡